Mersana Therapeutics, Inc. (MRSN) Reports Q2 Loss, Misses Revenue Estimates

Mersana Therapeutics, Inc. (MRSN) came out with a quarterly loss of $0.20 per share versus the Zacks Consensus Estimate of a loss of$ 0.18. This compares to loss of $0.47 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of -11.11%. A quarter ago, it was expected that this company would post a loss of$ 0.18 per share when it actually produced a loss of $0.16, delivering a surprise of 11.11%. Over the last four quarters, the compan ...